Banque Cantonale Vaudoise’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-327
Closed -$38K 1227
2023
Q3
$38K Hold
327
﹤0.01% 1002
2023
Q2
$34K Sell
327
-40
-11% -$4.22K ﹤0.01% 1013
2023
Q1
$40K Sell
367
-4,233
-92% -$468K ﹤0.01% 993
2022
Q4
$523K Hold
4,600
0.03% 437
2022
Q3
$285K Hold
4,600
0.02% 620
2022
Q2
$367K Sell
4,600
-727
-14% -$68.8K 0.02% 571
2022
Q1
$560K Hold
5,327
0.02% 529
2021
Q4
$573K Sell
5,327
-600
-10% -$65.5K 0.02% 544
2021
Q3
$649K Hold
5,927
0.03% 499
2021
Q2
$555K Hold
5,927
0.02% 568
2021
Q1
$546K Sell
5,927
-5,723
-49% -$483K 0.03% 519
2020
Q4
$852K Buy
11,650
+7,074
+155% +$526K 0.05% 346
2020
Q3
$355K Buy
4,576
+1,974
+76% +$136K 0.02% 531
2020
Q2
$145K Sell
2,602
-1,028
-28% -$44K 0.01% 726
2020
Q1
$108K Sell
3,630
-2,669
-42% -$90.3K 0.01% 752
2019
Q4
$228K Buy
+6,299
New +$193K 0.02% 693

Other funds holding HZNP

Banque Cantonale Vaudoise's HZNP Position: Q4 2023 in Review

Banque Cantonale Vaudoise sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 327 shares — an estimated $38K sold.

Banque Cantonale Vaudoise first reported a position in HZNP in Q4 2019 and held it in 16 quarters. The position peaked at $852K in Q4 2020. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Banque Cantonale Vaudoise reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Banque Cantonale Vaudoise sold 327 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $38K.
  • Banque Cantonale Vaudoise first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2019 and held it in 16 quarters.
  • Banque Cantonale Vaudoise's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $852K in Q4 2020.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Banque Cantonale Vaudoise's 13F filing for Q4 2023, filed 7 Feb 2024.